AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-18.28%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.29B
AUM Growth
+$2.29B
(-27%)
Cap. Flow
-$77.6M
Cap. Flow
% of AUM
-3.38%
Top 10 Holdings %
Top 10 Hldgs %
70.19%
Holding
122
New
8
Increased
14
Reduced
14
Closed
21
Top Buys
| 1 |
Neumora Therapeutics
NMRA
|
$39.5M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$23.4M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$12.3M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$11.8M |
| 5 |
Sagimet Biosciences
SGMT
|
$8.14M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$41.1M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$23.5M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$20.4M |
| 4 |
Relay Therapeutics
RLAY
|
$15.2M |
| 5 |
Protagonist Therapeutics
PTGX
|
$13.8M |
Sector Composition
| 1 | Healthcare | 55.33% |
| 2 | Consumer Discretionary | 43.57% |
| 3 | Technology | 0.62% |
| 4 | Communication Services | 0.2% |
| 5 | Real Estate | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
26
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $13.7M | 0.59% |
1,193,030
| – | – |
|
|
CBIO
27
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $12.9M | 0.55% |
8,589,064
| – | – |
|
|
RYZB
28
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $12.3M | 0.53% |
+555,556
| New | +$12.3M |
|
29
Geron
GERN
$887M
| $11.8M | 0.51% |
5,565,889
| – | – |
|
30
Roivant Sciences
ROIV
$8.58B
| $11.7M | 0.5% |
1,000,000
-625,000
| -38% | -$7.3M |
|
31
Taysha Gene Therapies
TSHA
$786M
| $11.6M | 0.5% |
3,663,104
+2,222,222
| +154% | +$7.02M |
|
32
Wave Life Sciences
WVE
$1.24B
| $11.5M | 0.49% |
2,000,000
-870,523
| -30% | -$5.01M |
|
33
Generation Bio
GBIO
$40.3M
| $10.7M | 0.46% |
2,814,191
| – | – |
|
34
Seer Inc
SEER
$114M
| $10.5M | 0.45% |
4,750,000
| – | – |
|
|
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
| $10.3M | 0.44% |
1,908,135
-3,056
| -0.2% | -$16.5K |
|
36
Cartesian Therapeutics
RNAC
$268M
| $9.69M | 0.42% |
9,136,635
| – | – |
|
37
Ovid Therapeutics
OVID
$91.7M
| $9.6M | 0.41% |
2,500,000
| – | – |
|
38
Erasca
ERAS
$391M
| $9.3M | 0.4% |
4,721,194
| – | – |
|
39
TSMC
TSM
$1.19T
| $8.93M | 0.38% |
102,699
+60,199
| +142% | +$5.23M |
|
40
Natera
NTRA
$22.8B
| $8.85M | 0.38% |
200,000
| – | – |
|
|
NBTX
41
Nanobiotix
NBTX
$415M
| $8.75M | 0.38% |
1,000,000
| – | – |
|
42
Intellia Therapeutics
NTLA
$1.25B
| $8.73M | 0.37% |
276,077
| – | – |
|
43
Foghorn Therapeutics
FHTX
$300M
| $8.6M | 0.37% |
1,720,720
| – | – |
|
44
Replimune Group
REPL
$456M
| $8.56M | 0.37% |
500,000
| – | – |
|
45
Repare Therapeutics
RPTX
$73.5M
| $8.46M | 0.36% |
700,000
| – | – |
|
|
46
Sagimet Biosciences
SGMT
$236M
| $8.14M | 0.35% |
+924,771
| New | +$8.14M |
|
|
IMA
47
ImageneBio, Inc. Common Stock
IMA
$152M
| $8.01M | 0.34% |
1,849,513
| – | – |
|
48
Aurinia Pharmaceuticals
AUPH
$1.56B
| $7.77M | 0.33% |
1,000,000
| – | – |
|
49
Viridian Therapeutics
VRDN
$1.58B
| $7.75M | 0.33% |
504,978
| – | – |
|
50
Dyne Therapeutics
DYN
$1.9B
| $7.3M | 0.31% |
815,085
| – | – |
|